A5009901118- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Brain Tumor Detection and Classification
- Artificial Intelligence in Healthcare and Education
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiation Therapy and Dosimetry
- Lung Cancer Research Studies
- Vascular Malformations Diagnosis and Treatment
- Meningioma and schwannoma management
Prince of Wales Hospital
2023-2025
Princess Margaret Cancer Centre
2007-2024
First-line pemetrexed-platinum chemotherapy + osimertinib(Pem-Plat-Osi) improves progression-free survival as compared to osimertinib alone in advanced epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, many patients are hesitant commence upfront. We describe outcomes Pem-Plat-Osi after first-line failure.
e20531 Background: First-line pemetrexed-platinum chemotherapy + osimertinib (Pem-Plat-Osi) improves progression free survival as compared to (Osi) alone in advanced epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, many patients are hesitant commence upfront. We describe the outcomes of who receive Pem-Plat-Osi after on first-line Osi 2 tertiary centres. Methods: Patients with EGFR-mutated (ex19del/L858R) NSCLC had between 1/7/2018-30/9/2023 at National...